
"Introducing a breakthrough new technique for sub-quadratic attention, making long-context LLMs 10x cheaper without sacrificing performance" Me:

By
–

"Introducing a breakthrough new technique for sub-quadratic attention, making long-context LLMs 10x cheaper without sacrificing performance" Me:
By
–
I love Zyphra, and it's amazing how much they can do in a small model but the reasoning is not yet ready (extremely long winded but still inaccurate). I am looking forward to the next update

By
–
Yesterday, Anthropic just released the API for this Dream, which is really fascinating. What it does is let the Claude agent "dream" on its own, organizing the memories it wrote down in past sessions—merging duplicates, updating expired ones, unifying contradictions, and even
By
–
Every day that goes by where @elonmusk doesn't try to kill this idea means we are marching down the nines. I'd say we are actually at 99.99%. Tomorrow we'll be at 99.999%. The day after 99.9999%. 🙂

By
–
http://
QUEBEC.AI unveils AI‑First Enterprise: the operating model for the intelligence era. From adoption to governed capability. Frontier. AI‑First. Sovereign. https://
quebecartificialintelligence.com/ai-first-enter
prise
… #QuebecAI #QuebecIA
By
–
OpenAI debuted several big updates for @ChatGPTapp ads, including a beta self-serve Ads Manager, new CPC bidding, conversion tracking, etc. For @Inc
, I wrote about ChatGPT ads moving beyond the controlled pilot phase, @OpenAI
’s approach to CPC bidding without explicit keywords,

By
–
I've always been passionate about games and they've played a big part in @GoogleDeepMind
’s history, as the perfect proving ground for AI. Thrilled to announce this research partnership with @FenrisCreations – @EveOnline is one of the most extraordinary games ever built and has an
By
–
"My AI agents are bankrupting me." I think that often when I see the bills that https://
alignednews.com/ai are running up. $150 a day sometimes to have my agents read my AI lists here on X. But then I remember what a Stanford education costs. $70,000 a year. And my agents
By
–
We're seeing major advances vs pancreatic cancer. Today @NEJM data for daraxonrasib @RevMedicines https://
nejm.org/doi/full/10.10
56/NEJMoa2505783?query=featured_home
…
Context for this first-in-class molecular glue https://
nejm.org/doi/full/10.10
56/NEJMoa2505783?query=featured_home
…